ArticleJournal for immunotherapy of cancer2017
Progressive hypoventilation due to mixed CD8
Article in Journal for immunotherapy of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.Annals of the rheumatic diseases · 2021Guideline
- Multimodal ultrasound for precise quantitative evaluation of diaphragmatic lesions in idiopathic inflammatory myopathy: a promising assessment tool.Quantitative imaging in medicine and surgery · 2026Article
- Review
- Lung Toxicity from Immune Checkpoint Inhibitors: A Diagnostic Approach.Journal of clinical medicine · 2025Review
- Muscle weakness, myositis and scleroderma induced by durvalumab.Respirology case reports · 2024Article
- Diaphragmatic Myopathy Associated with Dual Immune Checkpoint Inhibitors in a Patient with Renal Cell Carcinoma.Journal of immunotherapy and precision oncology · 2024Article
- Myositis with prominent B-cell aggregates causing shrinking lung syndrome in systemic lupus erythematosus: a case report.BMC rheumatology · 2022Article
- Not-so-opposite ends of the spectrum: CD8Nature immunology · 2021Review
- Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.Arthritis & rheumatology (Hoboken, N.J.) · 2021Review
- Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer.Frontiers in pharmacology · 2021Review
- Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review.Frontiers in oncology · 2021Article
- Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology.Clinical research in cardiology : official journal of the German Cardiac Society · 2020Review
- Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature.The oncologist · 2020Review
- Management of pulmonary toxicity associated with immune checkpoint inhibitors.European respiratory review : an official journal of the European Respiratory Society · 2019Review
- Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.Rheumatology (Oxford, England) · 2019Review
- Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.Rheumatology (Oxford, England) · 2019Review
- Checkpoint Inhibitors.Deutsches Arzteblatt international · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe combination of CTLA-4 and PD-L1 inhibitors has a manageable adverse effect profile, although rare immune-related adverse events (irAE) can occur. CASE PRESENTATION: We describe an autoimmune polymyositis following a partial response to combination tremelimumab and durvalumab for the treatment of recurrent lung adenocarcinoma. Radiography revealed significant reduction in all metastases; however, the patient developed progressive neuromuscular hypoventilation due to lymphocytic destruction of the diaphragmatic musculature. Serologic testing revealed a low level of de novo circulating antibodies against striated muscle fiber. Immunohistochemistry revealed type II muscle fiber atrophy with a mixed CD8
conclusionsThis case supports the hypothesis that muscle tissue is a target for lymphocytic infiltration in immune checkpoint inhibitor-associated polymyositis. Further insights into the autoimmune mechanism of PM will hopefully contribute to the prevention and treatment of this phenomenon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.